ライフサイエンスコーパス: neoadjuvant therapy

1 ol level <= 2.72 pg/mL [<= 10 pmol/L] during neoadjuvant therapy).

2 RI at 3 T at baseline and after one cycle of neoadjuvant therapy.

3 e may increase the probability of completing neoadjuvant therapy.

4 uch as stage, tumor location, and receipt of neoadjuvant therapy.

5 to high-risk patients who have not received neoadjuvant therapy.

6 tumor location, histologic subtype, or prior neoadjuvant therapy.

7 r patients according to their sensitivity to neoadjuvant therapy.

8 rline received FOLFIRINOX and 87 received no neoadjuvant therapy.

9 on within HER2-positive breast cancer during neoadjuvant therapy.

10 idual patients with breast cancer undergoing neoadjuvant therapy.

11 ase and delivering effective adjuvant and/or neoadjuvant therapy.

12 Thirty-five of 38 patients (92%) completed neoadjuvant therapy.

13 inked to age, diabetes, cardiac disease, and neoadjuvant therapy.

14 long-term benefit of trastuzumab-containing neoadjuvant therapy.

15 otable in terms of assessment of response to neoadjuvant therapy.

16 resection for rectal cancer with or without neoadjuvant therapy.

17 ries of resection after patient selection by neoadjuvant therapy.

18 ar period, tumor stage, tumor histology, and neoadjuvant therapy.

19 sectable ICCA using a combination of OLT and neoadjuvant therapy.

20 nosis" stage III with selective avoidance of neoadjuvant therapy.

21 Three of them underwent neoadjuvant therapy.

22 achievable in patients with RC treated with neoadjuvant therapy.

23 ve an emerging role in assessing response to neoadjuvant therapy.

24 g nodal status and complete responders after neoadjuvant therapy.

25 a novel means for evaluating prognosis after neoadjuvant therapy.

26 g nodal status and complete responders after neoadjuvant therapy.

27 of hepatocellular carcinoma and the role of neoadjuvant therapy.

28 a novel means for evaluating prognosis after neoadjuvant therapy.

29 CI, 44.1% to 78.4%) were node negative after neoadjuvant therapy.

30 blish a relatively high (28%) pCR rate after neoadjuvant therapy.

31 performed 4 to 10 weeks after completion of neoadjuvant therapy.

32 predictor of pathologic response to initial neoadjuvant therapy.

33 d levels of ER phosphorylation when given as neoadjuvant therapy.

34 clinically useful predictors of pCR to T/FAC neoadjuvant therapy.

35 cal failure, who are in need of an effective neoadjuvant therapy.

36 e most important prognostic indicators after neoadjuvant therapy.

37 ith high-risk features and respond poorly to neoadjuvant therapy.

38 Four (14%) had received prior adjuvant or neoadjuvant therapy.

39 py, and prior to surgery after completion of neoadjuvant therapy.

40 e part of standard pathology reporting after neoadjuvant therapy.

41 lower recurrence-free survival post adjuvant/neoadjuvant therapy.

42 ect patients who benefit from adjuvant after neoadjuvant therapy.

43 hieving pathological complete response after neoadjuvant therapy.

44 s but some T2 N0 patients might benefit from neoadjuvant therapy.

45 with matched clinicopathologic data, and no neoadjuvant therapy.

46 ong patients with breast cancer and RD after neoadjuvant therapy.

47 me biogenesis augmented the effectiveness of neoadjuvant therapy.

48 individuals with early breast cancer during neoadjuvant therapy.

49 of combination palbociclib plus letrozole as neoadjuvant therapy.

50 unresectable PDAC undergoing resection after neoadjuvant therapy.

51 20%), after a median duration of 5 months of neoadjuvant therapy.

52 ful in guiding treatment decisions regarding neoadjuvant therapy.

53 were willing to offer exploration following neoadjuvant therapy.

54 oesophageal junction treated with or without neoadjuvant therapy.

55 improve rectal cancer patient selection for neoadjuvant therapy.

56 nge) age of 63 (18-90) years; 78.1% received neoadjuvant therapy.

57 cer undergoing esophagectomy with or without neoadjuvant therapy.

58 onflicting results, especially in the era of neoadjuvant therapy.

59 ing esophagectomy is a valuable component of neoadjuvant therapy.

60 ophagus or esophagogastric junction received neoadjuvant therapy.

61 R imaging may help to assess the response to neoadjuvant therapy.

62 esection, of whom 88.8% received any form of neoadjuvant therapy.

63 ween 14 days and 6 weeks after completion of neoadjuvant therapy.

64 A minority (17.0%) had neoadjuvant therapy.

65 fy target pathways that may be exploited for neoadjuvant therapies.

66 n-resected patients were matched for time of neoadjuvant therapy (19.9 mo, P < 0.001).

67 CA19-9 (DeltaCA19-9) after the completion of neoadjuvant therapy; 3) normalization (CA19-9 <35 U/dL)

68 Following neoadjuvant therapy, 4 of 5 tumors were fluorescent; the

69 ts were studied (72.6% adenocarcinoma, 69.1% neoadjuvant therapy, 45.5% IS).

70 were tumor biology (80%), time interval from neoadjuvant therapy (61%), risk of becoming unresectable

71 raphy, endomucosal resection, esophagectomy, neoadjuvant therapy, adjuvant therapy, radiation alone,

72 ; these changes are dependent on the type of neoadjuvant therapy administered.

73 chemotherapeutics is being tested as part of neoadjuvant therapy after resection or loco-regional the

74 e have included chemoembolization before and neoadjuvant therapy after surgery, neither of which has

75 After neoadjuvant therapy, all parameters except CTvol showed

76 iopsy-confirmed metastasis before initiating neoadjuvant therapy allows for evaluation of response in

77 he addition of bevacizumab, as compared with neoadjuvant therapy alone, was associated with a higher

78 early stage disease after the completion of neoadjuvant therapies and tumor resection as well as to

79 nts with advanced PDAC who were treated with neoadjuvant therapy and had a pCR were identified betwee

80 patients underwent surgical resection after neoadjuvant therapy and had pathologic assessment of tum

81 ent of HTV after CRT is based on response to neoadjuvant therapy and has been shown to correlate with

82 pathologic complete response rates (pCRs) to neoadjuvant therapy and improve progression-free surviva

83 Exclusion criteria were neoadjuvant therapy and incomplete follow-up.

84 Compare survival after neoadjuvant therapy and liver transplantation with survi

85 up analysis of T1 and T2 rectal cancer after neoadjuvant therapy and local excision showed oncologica

86 recognizing the complexities of response to neoadjuvant therapy and moving beyond the binary paradig

87 ET/CT in the assessment of early response to neoadjuvant therapy and of response to therapy for metas

88 Primary tumor resection rates after neoadjuvant therapy and overall survival (OS) were the p

89 and perihilar CCA excluding individuals with neoadjuvant therapy and perioperative mortality between

90 2 patients with ypN + M0 rectal cancer after neoadjuvant therapy and radical anterior resection were

91 ediastinum and around the celiac trunk after neoadjuvant therapy and resection does not alter the TNM

92 We analyzed prognostic factors after neoadjuvant therapy and resection in 280 patients with i

93 using on the role of OLT in combination with neoadjuvant therapy and risk stratification of patients

94 ent outcome in the group of patients without neoadjuvant therapy and serves as a prognostic factor in

95 d was compared between patients who received neoadjuvant therapy and surgery (NEO) and patients who u

96 9 studies compared neoadjuvant therapy and surgery-first with adjuvant ther

97 with T3 to T4 or N1 to N2 LARC treated with neoadjuvant therapy and surgery.

98 Neoadjuvant therapy and treatment at an academic/researc

99 id not differ between patients who underwent neoadjuvant therapy and upfront surgery (88% vs 84%, P =

100 Age, diabetes, neoadjuvant therapy, and cardiac history predisposed (P<

101 y to be treated at academic centers, receive neoadjuvant therapy, and have higher T-stage and longer

102 predicted response to fluoropyrimidine-based neoadjuvant therapy, and implications of germline altera

103 us invasion and tumor deposits in LARC after neoadjuvant therapy, and its presence on restaging DW MR

104 fter controlling for comorbidity, receipt of neoadjuvant therapy, and nodal involvement, a longer sur

105 None received neoadjuvant therapy, and none had received adjuvant horm

106 iation of patient and tumor characteristics, neoadjuvant therapy, and operative factors with postoper

107 d tumor cells (DTC) that survive adjuvant or neoadjuvant therapy, and patients with detectable DTCs f

108 candidates for curative resection following neoadjuvant therapy, and recent reports of survival are

109 h node metastasis, reduced responsiveness to neoadjuvant therapy, and reduced overall survival.

110 stages I to III HER2-positive breast cancer, neoadjuvant therapy, and reports of both pCR and an even

111 or age, comorbidity, tumor stage, histology, neoadjuvant therapy, and surgeon volume.

112 Enrolment, neoadjuvant therapy, and surgery have been completed; ad

113 ge, tumor stage, previous abdominal surgery, neoadjuvant therapy, and surgical radicality did not inf

114 pathological tumor stage, surgical approach, neoadjuvant therapy, and weekday of surgery.

115 les and pathological complete response after neoadjuvant therapy are insufficient to fully capture bi

116 sponse (TRG 1) defines a unique cohort after neoadjuvant therapy, associated closely with nodal respo

117 tential to improve selection for surgery and neoadjuvant therapy, avoiding surgery in aggressive dise

118 stage III melanoma are ideal candidates for neoadjuvant therapy, because they represent a high-risk

119 Neoadjuvant therapy before cystectomy and consolidation

120 the long-term overall effects on survival of neoadjuvant therapy before surgery or radiation are unkn

121 tumor response in advanced-stage cases after neoadjuvant therapy before surgery.

122 in, nodal status, bone resection, and use of neoadjuvant therapy (before exenteration) on survival wa

123 ients receiving neoadjuvant FOLFIRINOX or no neoadjuvant therapy between April 2011 and February 2014

124 geal cancer treated by esophagectomy without neoadjuvant therapy between January 1988 and December 20

125 ell tolerated and beneficial as adjuvant and neoadjuvant therapy, but its utility in these settings c

126 locally advanced rectal cancer (LARC) after neoadjuvant therapy, but its value in detecting extramur

127 ancer with positive lymph nodes benefit from neoadjuvant therapy, but limitations in current clinical

128 nt and adjuvant therapies and surgery alone, neoadjuvant therapies combined with surgery compared wit

129 her N-stage, neoadjuvant chemotherapy, or no neoadjuvant therapy (compared with neoadjuvant chemoradi

130 Neoadjuvant therapy consisted of either chemotherapy or

131 Intense neoadjuvant therapy consisting of CRT followed by additi

132 e randomly assigned 1206 patients to receive neoadjuvant therapy consisting of docetaxel (100 mg per

133 n of an aging population, recent advances in neoadjuvant therapies, data supporting the oncologic eff

134 Although neoadjuvant therapy did not appear to prevent distant me

135 in inducing a response, but the response to neoadjuvant therapy did not predict outcome.

136 multivariable analysis, when controlling for neoadjuvant therapy, distance of tumor from anal verge,

137 o not achieve a pCR might still benefit from neoadjuvant therapy enabling breast-conserving surgery.

138 ancer received GLN (0.5 g/kg/day) during MTX neoadjuvant therapy, escalating from doses of 40 mg/m2 t

139 , or non-invasive disease, and those testing neoadjuvant therapy exclusively.

140 Neoadjuvant therapy experiments involved treating establ

141 When compared with no neoadjuvant therapy, FOLFIRINOX resulted in significantl

142 nt-free survival from trastuzumab-containing neoadjuvant therapy followed by adjuvant trastuzumab in

143 yield was demonstrated in patients receiving neoadjuvant therapy followed by esophagectomy.

144 most recent outcomes of a protocol involving neoadjuvant therapy followed by liver transplant for hil

145 ent recent data demonstrating the success of neoadjuvant therapy followed by liver transplantation fo

146 Recent data using a combination of neoadjuvant therapy followed by OLT in appropriately sel

147 Neoadjuvant therapy followed by planned esophagectomy ap

148 lar cholangiocarcinoma who were treated with neoadjuvant therapy followed up by liver transplantation

149 ents with perihilar cholangiocarcinoma using neoadjuvant therapy, followed by liver transplantation,

150 New diagnostic modalities, advances in neoadjuvant therapies for unresectable liver metastases,

151 All patients received imatinib neoadjuvant therapy for a median treatment period of 8.5

152 rch interest has been focused on the role of neoadjuvant therapy for all forms of resectable PDAC.

153 uct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recomm

154 age range, 45-70 years) scheduled to undergo neoadjuvant therapy for breast cancer underwent ultrason

155 orelbine, and trastuzumab is a highly active neoadjuvant therapy for HER2-overexpressing locally adva

156 and overall survival in patients who receive neoadjuvant therapy for high-grade extremity soft tissue

157 al, a multicenter, adaptive phase 2 trial of neoadjuvant therapy for high-risk clinical stage II or I

158 f docetaxel, vinorelbine, and trastuzumab as neoadjuvant therapy for human epidermal growth factor re

159 BoRT is an alternative to total neoadjuvant therapy for increasing organ preservation ra

160 In patients undergoing resection after neoadjuvant therapy for initially unresectable PDAC, pre

161 t high-resolution method in women undergoing neoadjuvant therapy for invasive breast cancers.

162 erial catheters/pumps and may have a role as neoadjuvant therapy for liver metastases that are unrese

163 However, for patients undergoing neoadjuvant therapy for locally advanced adenocarcinoma,

164 -) tumors while one came from a patient with neoadjuvant therapy for locally metastatic ER(low)/PR(-)

165 ents and end points when designing trials of neoadjuvant therapy for muscle-invasive bladder cancer (

166 Patients treated with neoadjuvant therapy for N2-positive stage IIIA NSCLC enj

167 pproach has the potential to be an effective neoadjuvant therapy for pancreatic cancer patients.

168 vel ICIs is an appealing option in trials of neoadjuvant therapy for patients with HCC, requiring eva

169 vaccination strategy might be developed as a neoadjuvant therapy for patients with PDA.

170 , well-tolerated, and efficacious regimen as neoadjuvant therapy for patients with squamous cell carc

171 nts opting for nonoperative management after neoadjuvant therapy for rectal cancer.

172 Neoadjuvant therapy for regional metastases might improv

173 The optimal neoadjuvant therapy for resectable pancreatic ductal ade

174 ctomy for patients undergoing multimodality (neoadjuvant) therapy for adenocarcinoma of the esophagus

175 ients with complete pathological response to neoadjuvant therapy had uniformly favorable outcomes, th

176 Pathologic complete response (pCR) following neoadjuvant therapy has been associated with improved ev

177 rderline resectable PC and, at some centers, neoadjuvant therapy has been extended to patients with r

178 demonstrated that single-agent paclitaxel as neoadjuvant therapy has significant antitumor activity,

179 maging modalities, and the widespread use of neoadjuvant therapy have all contributed to these improv

180 Patient demographics, neoadjuvant therapy, histopathological assessment, lengt

181 d OS compared with White race when receiving neoadjuvant therapy (HR, 0.78 [95% CI, 0.67-0.90]).

182 odel, prevented metastatic disease following neoadjuvant therapy in a triple-negative mammary carcino

183 -3 and similar drugs could be candidates for neoadjuvant therapy in cancers with a functional p53.

184 tion could be made for or against the use of neoadjuvant therapy in cutaneous melanoma.

185 Stratification of neoadjuvant therapy in FOLFIRINOX-based, gemcitabine-bas

186 ts of letrozole plus lapatinib or placebo as neoadjuvant therapy in hormone receptor (HR) -positive/h

187 to develop recommendations for investigating neoadjuvant therapy in melanoma to align future trial de

188 A pCR following neoadjuvant therapy in patients with advanced PDAC is as

189 moradiation treatment (CRT) has been used as neoadjuvant therapy in patients with borderline resectab

190 CT was unable to detect any response to neoadjuvant therapy in this group.

191 The expected response rate to T/FAC neoadjuvant therapy in unselected patients is 28%.

192 Appropriate candidates for neoadjuvant therapy include patients with inflammatory b

193 studied during the last decade with various neoadjuvant therapies including chemotherapy and combina

194 Patients who complete all intended neoadjuvant therapy, including surgery, experience an ov

195 g that grades III to IV toxic effects during neoadjuvant therapy increase POM has significant implica

196 Neoadjuvant therapy increased the risk of 30-day morbidi

197 odalities as well as the use of adjuvant and neoadjuvant therapies is still debated.

198 Total neoadjuvant therapy is a new paradigm for rectal cancer

199 The esophagectomy with neoadjuvant therapy is also in immunosuppressant patient

200 The role of adjuvant or neoadjuvant therapy is being investigated, but there is

201 The role of adjuvant or neoadjuvant therapy is being investigated, but there is

202 after a complete clinical response (cCR) to neoadjuvant therapy is controversial.

203 Although neoadjuvant therapy is currently seen as not effective i

204 Surgical resection of LAPC after neoadjuvant therapy is feasible in a highly selected coh

205 Neoadjuvant therapy is increasingly used to control loca

206 Neoadjuvant therapy is now an active area of research fo

207 Neoadjuvant therapy is recommended for patients with bor

208 ronous disease should be dealt with; whether neoadjuvant therapy is useful or harmful for these patie

209 rapy and/or chemoradiation prior to surgery (neoadjuvant therapy) is increasingly recognized as the p

210 e II/III) demonstrated that females received neoadjuvant therapy less frequently than males and had w

211 t local excision of T1-2 rectal cancer after neoadjuvant therapy may be safe.

212 y selected patients with advanced iCCA after neoadjuvant therapy may benefit from liver transplantati

213 y selected patients with advanced iCCA after neoadjuvant therapy may benefit from LT under research p

214 Curative surgery for VTT is high-risk, but neoadjuvant therapy may improve outcomes.

215 Neoadjuvant therapy may improve survival; however, it do

216 In conclusion neoadjuvant therapy may offer benefit over surgery-first

217 Despite important progress in adjuvant and neoadjuvant therapies, metastatic disease often develops

218 espite being the standard-of-care treatment, neoadjuvant therapy (NAT) attains a complete response on

219 erall survival between patients who received neoadjuvant therapy (NAT) followed by resection and thos

220 Early-stage breast cancers resistant to neoadjuvant therapy (NAT), characterized by high residua

221 cinoma (PDAC) have undergone resection after neoadjuvant therapy (NAT).

222 AEG, 650 underwent radical surgery, 55% post-neoadjuvant therapy (NeoT).

223 Following neoadjuvant therapy, normalization of CA19-9, rather tha

224 ic leakage at any time during follow-up were neoadjuvant therapy (odds ratio 2.85; 95% confidence int

225 potential for application to prevention and neoadjuvant therapy of early breast cancer.

226 irinox is a valuable treatment option in the neoadjuvant therapy of PDAC.

227 tential role of FDG-PET in the monitoring of neoadjuvant therapy of soft-tissue and musculoskeletal s

228 We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for

229 ssess the effect of surgical resection after neoadjuvant therapy on patient outcomes.

230 ith respect to medical comorbidities, use of neoadjuvant therapy, operative outcomes, postoperative c

231 DNA) detection at clinical diagnosis, during neoadjuvant therapy, or after resection may discern high

232 Total neoadjuvant therapy, or systemic induction chemotherapy

233 ecisely evaluate and predict the response to neoadjuvant therapies over several weeks.

234 osite ratios/scores showed correlations with neoadjuvant therapy (p < 0.001).

235 plete resections or tumor progression during neoadjuvant therapy (P < 0.01).

236 After neoadjuvant therapy, patients underwent axillary surgery

237 ostic tools and early diagnosis might enable neoadjuvant therapy (possibly aimed at oxidative stress)

238 For DP, female sex and the absence of neoadjuvant therapy predicted better TO rates (OR 1.38 [

239 g, the histological type and the response to neoadjuvant therapy predicted the time frame of relapse;

240 sis (pretx), after completion of all planned neoadjuvant therapy (preop), and after surgery (postop)

241 eas patients with residual tumor cells after neoadjuvant therapy primarily experienced relapse within

242 Among those who received neoadjuvant therapy, proportional differences in patholo

243 f success in a confirmatory phase 3 trial of neoadjuvant therapy reached a prespecified threshold for

244 Clinical details, including the neoadjuvant therapy received, should accompany the patho

245 ed EFS/OS in patients with TNBC who received neoadjuvant therapy, regardless of pCR status.

246 The role of EUS in restaging following neoadjuvant therapy remains controversial, with recent s

247 Restaging following neoadjuvant therapy remains suboptimal.

248 ation, particularly for advanced cancers and neoadjuvant therapies, require continued assessment.

249 courage studies of both unresectable and (as neoadjuvant therapy) resectable tumors.

250 rcinoma, which shows promise for determining neoadjuvant therapy response and for detecting locally a

251 igated as emerging techniques for evaluating neoadjuvant therapy response for patients with primary b

252 rganoids may provide a readout predictive of neoadjuvant therapy response to radiation in rectal canc

253 linical trial eligibility, and assessment of neoadjuvant therapy response.

254 Akt inhibitor MK-2206 combined with standard neoadjuvant therapy resulted in higher estimated pCR rat

255 A subgroup analysis of neoadjuvant therapies showed a superior effectiveness of

256 ith HER2-positive breast cancer treated with neoadjuvant therapies that target HER2.

257 In patients not receiving neoadjuvant therapy, the goal for patients with adenocar

258 Despite the clear potential benefits of neoadjuvant therapy, the optimal neoadjuvant regimen for

259 stology and residual nodal involvement after neoadjuvant therapy, the risk of brain metastases was 53

260 n tumor accumulation of FDG during and after neoadjuvant therapy; these changes are dependent on the

261 Excluded were patients who received neoadjuvant therapy, those whose staging information was

262 l, tumor marker and pathological response to neoadjuvant therapy, time to recurrence, patterns of fai

263 tumor response following completion of total neoadjuvant therapy (TNT) in patients with locally advan

264 iterature on the treatment outcomes of total neoadjuvant therapy (TNT) on locally advanced rectal can

265 uctal adenocarcinoma (PDAC) undergoing total neoadjuvant therapy (TNT).

266 ly advanced rectal cancer treated with total neoadjuvant therapy (TNT); however, prospective studies

267 repair locally advanced rectal cancer, total neoadjuvant therapy (TNT; ie chemoradiation [CRT] and ch

268 t adjuvants to surgical resection, including neoadjuvant therapy to downstage tumors prior to planned

269 to determine whether PVE can be used during neoadjuvant therapy to enhance growth of future residual

270 al verge were randomized after completion of neoadjuvant therapy to laparoscopic or open resection.

271 Neoadjuvant therapy, tumor size, node positivity, and ma

272 ession, adjusted for age, sex, co-morbidity, neoadjuvant therapy, tumour stage, tumour histology, sur

273 er of LAPC patients who respond favorably to neoadjuvant therapy undergo surgical resection.

274 Neoadjuvant therapy using the fluorouracil, doxorubicin,

275 The use of neoadjuvant therapy, variation in the prostate-specific

276 Exclusion criteria were neoadjuvant therapy, vascular- and unrelated organ resec

277 5-year AR survival for neoadjuvant therapy was 0.2069 (0.0323-0.3300) versus 0.

278 2-year survival AR for neoadjuvant therapy was 0.5178 (0.3000-0.5970) versus 0.

279 1-year survival AR for neoadjuvant therapy was 0.7969 (0.6061-0.9500) versus 0.

280 Aggregate rate (AR) of R0 resection for neoadjuvant therapy was 0.8008 (0.3636-0.9144) versus 0.

281 The clinical response rate to neoadjuvant therapy was 97%, 28% of patients had a compl

282 et analysis of only those patients receiving neoadjuvant therapy was also performed.

283 atients with resected pT3 tumors and without neoadjuvant therapy was analyzed.

284 Neoadjuvant therapy was significantly (P=0.004) associat

285 e-intensive and time-intensive multimodality neoadjuvant therapy was successfully administered to a m

286 able site of EHD, and progression of CRLM on neoadjuvant therapy were associated with overall surviva

287 changes in (18)F-fluciclovine avidity after neoadjuvant therapy were compared to breast cancer thera

288 Patients taking BBs at the start of neoadjuvant therapy were compared with patients with no

289 o underwent complete gross resection without neoadjuvant therapy were identified from a prospectively

290 y with en bloc 2-field lymphadenectomy after neoadjuvant therapy were included, and survival was anal

291 with soft-tissue sarcomas who had undergone neoadjuvant therapy were reviewed by two readers during

292 Aim of the study was the evaluation of neoadjuvant therapy with a focus on Folfirinox.

293 Neoadjuvant therapy with chemotherapy or chemoradiothera

294 573 patients enrolled in 6 clinical trials, neoadjuvant therapy with DCPI was associated with higher

295 ine increased 2- to 3-fold after one dose of neoadjuvant therapy with FOLFIRINOX in sensitive human P

296 olid tumors and detectable ctDNA, undergoing neoadjuvant therapy with ICIs.

297 been further evaluated, both as adjuvant and neoadjuvant therapy with radiation therapy or radical pr

298 (P = 0.02) from 16% at diagnosis to 31% post-neoadjuvant therapy, with loss of LBM (-3.0 +/- 5.4 kg,

299 ches combined terms for "breast cancer" and "neoadjuvant therapy," with no limit on publication date.

300 ved standard taxane- and anthracycline-based neoadjuvant therapy without (control) or with oral MK-22